198 related articles for article (PubMed ID: 34648082)
1. Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
Iwasa-Inoue N; Nomura H; Kataoka F; Chiyoda T; Yoshihama T; Nanki Y; Sakai K; Kobayashi Y; Yamagami W; Morisada T; Hirasawa A; Aoki D
Int J Clin Oncol; 2022 Feb; 27(2):441-447. PubMed ID: 34648082
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
Yoshihama T; Nomura H; Iwasa N; Kataoka F; Hashimoto S; Nanki Y; Hirano T; Makabe T; Sakai K; Yamagami W; Hirasawa A; Aoki D
Jpn J Clin Oncol; 2017 Nov; 47(11):1019-1023. PubMed ID: 28973541
[TBL] [Abstract][Full Text] [Related]
3. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
Ebata T; Yunokawa M; Bun S; Shimomura A; Shimoi T; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1283-1288. PubMed ID: 27832327
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.
Komiyama S; Kugimiya T; Kubushiro K
J Surg Oncol; 2018 Sep; 118(4):687-693. PubMed ID: 30206937
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
7. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
[TBL] [Abstract][Full Text] [Related]
8. Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
Park SJ; Shim SH; Ji YI; Kwon SH; Lee EJ; Lee M; Chang SJ; Park S; Kim SY; Lee SJ; Kim JW; Roh JW; Lee SH; Song T; Kim HS
BMC Cancer; 2020 May; 20(1):385. PubMed ID: 32375688
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
Onda T; Kobayashi H; Nakanishi T; Hatae M; Iwasaka T; Konishi I; Shibata T; Fukuda H; Kamura T; Yoshikawa H
Gynecol Oncol; 2009 Apr; 113(1):57-62. PubMed ID: 19181369
[TBL] [Abstract][Full Text] [Related]
10. Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
Chou HH; Chen WC; Yang LY; Huang HJ; Chang WY; Lin H; Wu RC; Chen MY; Qiu JT; Huang KG; Chao A; Chang TC; Lai CH
Eur J Obstet Gynecol Reprod Biol; 2021 Jul; 262():13-20. PubMed ID: 33984725
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
[TBL] [Abstract][Full Text] [Related]
14. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
15. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
16. Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.
Ueda A; Watari H; Mandai M; Fukuhara S; Sugitani Y; Ogino K; Kamijima S; Enomoto T
J Gynecol Oncol; 2022 Nov; 33(6):e78. PubMed ID: 36245228
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Tiersten AD; Liu PY; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
Gynecol Oncol; 2009 Mar; 112(3):444-9. PubMed ID: 19138791
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Rouzier R; Gouy S; Selle F; Lambaudie E; Floquet A; Fourchotte V; Pomel C; Colombo PE; Kalbacher E; Martin-Francoise S; Fauvet R; Follana P; Lesoin A; Lecuru F; Ghazi Y; Dupin J; Chereau E; Zohar S; Cottu P; Joly F
Eur J Cancer; 2017 Jan; 70():133-142. PubMed ID: 27914243
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Takaya H; Nakai H; Murakami K; Tobiume T; Suzuki A; Mandai M; Matsumura N
Int J Clin Oncol; 2018 Aug; 23(4):698-706. PubMed ID: 29572761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
